GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Meribank Biotech Co Ltd (ROCO:4724) » Definitions » Debt-to-EBITDA

Meribank Biotech Co (ROCO:4724) Debt-to-EBITDA : -0.35 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Meribank Biotech Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Meribank Biotech Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$19.2 Mil. Meribank Biotech Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was NT$14.8 Mil. Meribank Biotech Co's annualized EBITDA for the quarter that ended in Dec. 2023 was NT$-98.2 Mil. Meribank Biotech Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.35.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Meribank Biotech Co's Debt-to-EBITDA or its related term are showing as below:

ROCO:4724' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.34   Med: -0.71   Max: -0.37
Current: -0.37

During the past 6 years, the highest Debt-to-EBITDA Ratio of Meribank Biotech Co was -0.37. The lowest was -2.34. And the median was -0.71.

ROCO:4724's Debt-to-EBITDA is ranked worse than
100% of 275 companies
in the Biotechnology industry
Industry Median: 1.36 vs ROCO:4724: -0.37

Meribank Biotech Co Debt-to-EBITDA Historical Data

The historical data trend for Meribank Biotech Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Meribank Biotech Co Debt-to-EBITDA Chart

Meribank Biotech Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial -0.71 -2.34 -0.77 -0.65 -0.37

Meribank Biotech Co Semi-Annual Data
Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.53 -0.72 -0.65 -0.43 -0.35

Competitive Comparison of Meribank Biotech Co's Debt-to-EBITDA

For the Biotechnology subindustry, Meribank Biotech Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Meribank Biotech Co's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Meribank Biotech Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Meribank Biotech Co's Debt-to-EBITDA falls into.



Meribank Biotech Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Meribank Biotech Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(19.228 + 14.811) / -92.563
=-0.37

Meribank Biotech Co's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(19.228 + 14.811) / -98.166
=-0.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Dec. 2023) EBITDA data.


Meribank Biotech Co  (ROCO:4724) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Meribank Biotech Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Meribank Biotech Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Meribank Biotech Co (ROCO:4724) Business Description

Traded in Other Exchanges
N/A
Address
Sector 1, Neihu Road, 1st Floor, No.68, Neihu District, Taipei, TWN, 11493
Meribank Biotech Co Ltd is engaged in Research and development and sales of new cell drugs and also Umbilical cord blood, placenta and umbilical cord mesenchymal stem cells processing, testing and cryopreservation.

Meribank Biotech Co (ROCO:4724) Headlines

No Headlines